Premises: Universal childhood immunization against measles, mumps and rubella is recommended. Some doubt has arised on the efficacy of some vaccine strains due to their weak immunogenicity. Objective: To compare the safety, reactogenicity and immunogenicity of a new MMR vaccine (Priorix, Smithkline Beecham Biologicals) containing live attenuated Schwarz strain (Measles), Rit 4385 strain (Mumps), RA 27/3 strain (Rubella) and of an established reference and widely used in Italy vaccine (Triviraten, Berna) containing Edmonston- Zagreb strain (Measles), Rubini strain (Mumps), RA 27/3 strain (Rubella). Methods: A hundred and fifty-eight healthy children 12 to 24 month old were enrolled in a blinded, randomized study to receive a single dose of one of the two vaccines. Safety and reactogenicity were assessed by a solicited follow-up of local and general adverse experiences, performed by the parents of the vaccines, on the day of vaccination and during the 42 subsequent days. Immunogenicity was assessed by measuring the specific antibody levels against mumps, measles and rubella in two serum samples obtained before and 6 weeks after vaccination, using a commercial immunoassay kit. Results: Local and general reactions were mild without any significant difference between the two vaccines groups. The rates of seroconversion for measles, mumps, rubella were 98.5%, 98.5%, 100%, respectively, in Priorix group and 100%, 30%, 100%, respectively, in Triviraten group. Mean antibody geometric titres were significantly higher with Schwarz strain (2766 mUI/ml) than with Edmonston- Zagreb strain (836 mUI/ml) and with Rit 4385 strain (1697 mUI/ml) that with Rubini strain (183 mUI/ml). Conclusions: The new SB MMR vaccine seems well balanced in terms of tolerability and highly immunogenicity for all the three viral components.
|Number of pages||5|
|Journal||Rivista Italiana di Pediatria|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health